Details
| Stereochemistry | ACHIRAL |
| Molecular Formula | 3Cl.Ga |
| Molecular Weight | 173.287 |
| Optical Activity | NONE |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
[Cl-].[Cl-].[Cl-].[67Ga+3]
InChI
InChIKey=UPWPDUACHOATKO-MPZFSRPWSA-K
InChI=1S/3ClH.Ga/h3*1H;/q;;;+3/p-3/i;;;1-3
Gallium citrate Ga 67 is the citrate salt of the radioisotope gallium Ga 67. Although the mechanism is unknown, gallium Ga 67 concentrates in lysosomes and is bound to a soluble intracellular protein in certain viable primary and metastatic tumors and focal sites of inflammation, allowing scintigraphic localization. Ga-67 scintigraphy (GS) cannot differentiate between tumor and acute inflammation. Gallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state.
Approval Year
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
| Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
|||
| Primary | GALLIUM CITRATE GA 67 Approved UseGallium Citrate Ga 67 Injection may be useful in demonstrating the presence of the following malignancies: Hodgkins disease, lymphomas and bronchogenic carcinoma. Positive Ga 67 uptake in the absence of prior symptoms warrants follow-up as an indication of a potential disease state. Launch Date1976 |
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DB14550
Created by
admin on Mon Mar 31 19:16:03 GMT 2025 , Edited by admin on Mon Mar 31 19:16:03 GMT 2025
|
PRIMARY | |||
|
A04B19O2B0
Created by
admin on Mon Mar 31 19:16:03 GMT 2025 , Edited by admin on Mon Mar 31 19:16:03 GMT 2025
|
PRIMARY | |||
|
314639
Created by
admin on Mon Mar 31 19:16:03 GMT 2025 , Edited by admin on Mon Mar 31 19:16:03 GMT 2025
|
PRIMARY | RxNorm | ||
|
73415785
Created by
admin on Mon Mar 31 19:16:03 GMT 2025 , Edited by admin on Mon Mar 31 19:16:03 GMT 2025
|
PRIMARY | |||
|
A04B19O2B0
Created by
admin on Mon Mar 31 19:16:03 GMT 2025 , Edited by admin on Mon Mar 31 19:16:03 GMT 2025
|
PRIMARY |
ACTIVE MOIETY
SUBSTANCE RECORD